Zacks Investment Research upgraded shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) from a sell rating to a hold rating in a research report released on Tuesday.
According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
Several other analysts have also recently weighed in on AIMT. JMP Securities initiated coverage on shares of Aimmune Therapeutics in a research note on Monday, September 26th. They issued an outperform rating and a $30.00 price target for the company. Piper Jaffray Cos. reissued an overweight rating and issued a $38.00 price target on shares of Aimmune Therapeutics in a research note on Friday, September 23rd. Wedbush reissued an outperform rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research note on Wednesday, September 21st. Finally, Credit Suisse Group AG reissued a buy rating and issued a $35.00 price target on shares of Aimmune Therapeutics in a research note on Friday, August 19th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Aimmune Therapeutics currently has a consensus rating of Buy and an average price target of $32.20.
Aimmune Therapeutics (NASDAQ:AIMT) opened at 16.26 on Tuesday. Aimmune Therapeutics has a 52 week low of $9.77 and a 52 week high of $22.01. The company’s market cap is $687.05 million. The company has a 50-day moving average of $16.19 and a 200-day moving average of $13.96.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.01. On average, equities research analysts predict that Aimmune Therapeutics will post ($1.75) EPS for the current year.
In related news, insider Mary M. Rozenman sold 30,000 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $16.80, for a total transaction of $504,000.00. Following the completion of the transaction, the insider now owns 30,000 shares of the company’s stock, valued at approximately $504,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mary M. Rozenman sold 25,000 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $16.80, for a total transaction of $420,000.00. Following the transaction, the insider now directly owns 25,000 shares of the company’s stock, valued at approximately $420,000. The disclosure for this sale can be found here. Corporate insiders own 24.56% of the company’s stock.
Several institutional investors have recently bought and sold shares of AIMT. Metropolitan Life Insurance Co. NY boosted its position in Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock worth $130,000 after buying an additional 797 shares during the last quarter. Emerald Acquisition Ltd. acquired a new stake in Aimmune Therapeutics during the second quarter worth about $154,000. American International Group Inc. raised its stake in Aimmune Therapeutics by 135.7% in the second quarter. American International Group Inc. now owns 15,131 shares of the company’s stock worth $164,000 after buying an additional 8,711 shares during the period. Nationwide Fund Advisors raised its stake in Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock worth $183,000 after buying an additional 9,495 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in Aimmune Therapeutics during the second quarter worth about $186,000. 69.22% of the stock is owned by hedge funds and other institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.